Keuangan Elevance Health (ELV)
NYSE · Healthcare · Medical - Healthcare Plans · Karyawan: 96.615 · CEO: Gail Koziara Boudreaux
- Harga
- $420,07 -0,46%
- Kapitalisasi pasar
- $91,1 M
- Nilai perusahaan
- $112 M
- Laporan terakhir
- Q3 '26 diajukan 2026-10-21
- Laporan berikutnya
- 2027-01-27 Estimasi EPS: $2,08
Pendapatan (TTM)$202 M+3,6% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)3,7%-0,7 poin vs tahun laluLaba operasional: $7,46 M
Laba bersih (TTM)$5,14 M-7,1% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)$6,51 M+72,9% vs tahun laluCapex: $1,08 M
EPS dilusian (TTM)$23,45-4,1% vs tahun laluJumlah 4 kuartal terakhir
Kas neto$7,09 M+130,3% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $91,1 M EV $112 M
- Pendapatan
- $202 M 12 bulan terakhir
- Pertumbuhan pendapatan
- 0% Konsensus FY2026
- Margin laba
- 2,5% Laba bersih / pendapatan, TTM
- P/E
- 17,9× Forward 14,5× (FY2026)
- P/S
- 0,5× Harga / penjualan, TTM
- EV / EBITDA
- 12,6× TTM
- Arus kas bebas
- $6,51 M 12 bulan terakhir
- Laba bersih
- $5,14 M 12 bulan terakhir
- Estimasi pendapatan
- $200 M Konsensus FY2026
- Laba
- 2027-01-27 Estimasi pendapatan: $49,4 M
- Dividen
- $6,87 Per saham, 12 bulan terakhir
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-10-21): pendapatan melampaui 2,4%, EPS melampaui 48,4%Pendapatan $50,4 M vs $49,3 M yang diharapkan (+2,4%); EPS $6,99 vs $4,71 (+48,4%).
- Pertumbuhan pendapatan melambat: 1,4% yoyPendapatan Q3 '26: $51,4 M, rata-rata empat kuartal sebelumnya: 6,5%.
- Margin operasional 3,7% (TTM), dibanding tahun lalu: -0,7 poinLaba operasional tumbuh -12,0%, pendapatan tumbuh 3,6%.
- 19,3% dari laba sebelum pajak tergerus kerugian non-operasionalLaba sebelum pajak $6,25 M vs laba operasional $7,46 M (TTM). Kerugian dari kepemilikan saham dan pos sekali-pakai lainnya menekan laba bersih dan EPS - laba operasional adalah ukuran bisnis yang lebih bersih.
- Capex: 0,5% dari pendapatan (tahun lalu 0,6%)$1,08 M diinvestasikan dalam 4 kuartal terakhir (-5,5% dibanding tahun sebelumnya). Arus kas bebas: $6,51 M = 126,8% dari laba bersih.
- $3,66 M dikembalikan ke pemegang saham = 56,2% dari arus kas bebasBuyback: $2,16 M (tahun lalu $3,95 M), dividen: $1,5 M, kompensasi saham: $240 jt (TTM).
- Jumlah saham dilusian turun dalam setahun: 3,6%Saham dilusian pada Q3 '26: 218 jt, setahun sebelumnya: 226 jt.
- Kas neto: $7,09 MKas + investasi jangka pendek: $37,8 M, utang termasuk sewa: $30,8 M; tahun lalu utang neto: $23,4 M.
- Reportable Segments: pendapatan +1,4%, margin 2,5% (sebelumnya 2,6%)Segmen pelaporan dengan pertumbuhan tercepat pada Q3 '26: laba operasional $1,27 M dari pendapatan $51,4 M (dari catatan segmen dalam laporan).
Kuartal terakhir: Q3 '26
Kuartal berakhir 2026-09-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q3 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $51,4 M | $50,7 M | +1,4% |
| Margin kotor | 15,6% | 24,8% | -9,2 poin |
| Laba operasional | $2,15 M | $1,76 M | +22,5% |
| Margin operasional | 4,2% | 3,5% | +0,7 poin |
| Laba bersih | $1,37 M | $1,19 M | +14,8% |
| EPS dilusian | $6,27 | $5,32 | +17,9% |
| Arus kas operasional | $1,27 M | $1,14 M | +11,6% |
| Capex | $267 jt | $360 jt | -25,8% |
| Arus kas bebas | $1 M | $775 jt | +29,0% |
| R&D | $0 | $0 | – |
| Kompensasi berbasis saham | $80 jt | $84 jt | -4,8% |
Dilaporkan vs konsensus
2026-10-21| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $50,4 M | $49,3 M | +2,4% |
| EPS (basis konsensus) | $6,99 | $4,71 | +48,4% |
Dari laporan 2026-10-21 untuk Q3 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q3 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Health Benefits Segment | $43,4 M | +2,6% | 86,0% | $170 M | +4,6% | |
| Carelon Services Segment | $19,3 M | +5,4% | 38,3% | $75,2 M | +41,7% | |
| Segment Eliminations | -$12,2 M | – | -24,2% | – | – |
Laba segmen
Laba operasional per segmen pelaporan, dibaca dari catatan segmen setiap 10-Q / 10-K (rincian laba yang tidak ada di sebagian besar data feed).
Segmen pada Q3 '26
| Segmen | Pendapatan | yoy | Laba operasional | yoy | Margin | Margin tahun lalu | Laba operasional TTM |
|---|---|---|---|---|---|---|---|
| Reportable Segments | $51,4 M | +1,4% | $1,27 M | -2,0% | 2,5% | 2,6% | $5,43 M |
| Health Benefits Segment | – | – | $436 jt | -27,5% | – | – | $3,27 M |
| Carelon Rx Segment | – | – | $616 jt | +10,8% | – | – | $2,5 M |
| Carelon Services Segment | – | – | $292 jt | +33,3% | – | – | $978 jt |
| Carelon Total | – | – | – | – | – | – | – |
| Corporate And Other | – | – | -$75 jt | +7,4% | – | – | -$1,32 M |
| Total Carelon | – | – | $908 jt | +17,2% | – | – | $3,48 M |
Laba operasional per segmen
kuartalanMargin operasional segmen
kuartalanKuartal keempat dihitung: 10-K melaporkan setahun penuh, dikurangi tiga kuartal dari 10-Q.
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- $7,6 M
- Capex
- -$1,08 M
- Buyback
- -$2,16 M
- Dividen
- -$1,5 M
- Akuisisi
- $35 jt
- Utang neto diterbitkan
- $415 jt
- Kompensasi berbasis saham
- $240 jt
- Arus kas bebas
- $6,51 M
- Dikembalikan ke pemegang saham / FCF
- 56,2%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | 17,9× | 17,2× | 13,9× – 20,9× |
| EV / EBITDA | 12,6× | 12,1× | 10,5× – 14,0× |
| EV / Penjualan | 0,6× | 0,8× | 0,5× – 1,0× |
| Harga / FCF | 14,0× | 18,4× | 15,5× – 24,5× |
| Harga / Nilai buku | 2,0× | 2,6× | 1,8× – 3,4× |
| Imbal hasil FCF | 7,2% | 5,6% | 4,1% – 6,4% |
| Imbal hasil modal yang diinvestasikan | 7,5% | 7,3% | 6,6% – 8,2% |
| Imbal hasil ekuitas | 11,6% | 15,2% | 12,9% – 16,9% |
Analis
Target konsensus $466,69 (+11,1%)
rentang $395,00 – $523,00 · peringkat Buy
Beli kuat0
Beli27
Tahan11
Jual0
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $200 M | +0,5% | $29,05 | +15,6% | 14,5× | 12 |
| FY2027 | $205 M | +2,5% | $30,25 | +4,1% | 13,9× | 12 |
| FY2028 | $213 M | +4,0% | $34,62 | +14,4% | 12,1× | 5 |
| FY2029 | $217 M | +1,8% | $39,97 | +15,5% | 10,5× | 1 |
| FY2030 | $238 M | +9,7% | $46,39 | +16,1% | 9,1× | 1 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 395 angka yang ditandai Elevance Health Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable and Accrued Liabilities, Current | $8,32 M | $6,09 M | +36,6% | $7,32 M | $6,93 M | +5,7% |
| Accounts Receivable, Allowance for Credit Loss, Recovery | -$108 jt2025-12-31 | – | – | $129 jt | – | – |
| Accounts Receivable, Allowance for Credit Loss, Writeoff | – | – | – | $264 jt | – | – |
| Accrued Income Taxes, Current | $685 jt | $141 jt | +385,8% | $151 jt | $75 jt | +101,3% |
| Accrued Investment Income Receivable | $308 jt | $280 jt | +10,0% | $295 jt | $287 jt | +2,8% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $4,06 M2025-12-31 | $3,68 M | +10,3% | $4,06 M | $3,68 M | +10,3% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$1,68 M | -$543 jt | -208,7% | -$451 jt | -$1,15 M | +60,7% |
| Additional Paid in Capital | $8,99 M | $8,91 M | +0,9% | $8,94 M | $8,91 M | +0,3% |
| Allowance for Doubtful Other Receivables, Current | $1,76 M | $1,47 M | +19,6% | $1,51 M | $1,39 M | +9,0% |
| Amortization of Intangible Assets | $106 jt | $162 jt | -34,6% | $628 jt | $580 jt | +8,3% |
| Asset Impairment Charges | $33 jt | $70 jt | -52,9% | $108 jt | $103 jt | +4,9% |
| Assets | $128 M | $123 M | +4,1% | $121 M | $117 M | +3,9% |
| Assets Held by Insurance Regulators | $1,12 M2025-12-31 | $1,04 M | +8,3% | $1,12 M | $1,04 M | +8,3% |
| Assets Held-for-sale, Not Part of Disposal Group, Current | $02025-12-31 | $490 jt | -100,0% | $0 | $490 jt | -100,0% |
| Assets, Current | $68,5 M | $63,8 M | +7,4% | $63 M | $58,9 M | +6,9% |
| Assets, Fair Value Disclosure | $37,5 M | $34,8 M | +7,8% | $35,7 M | $33 M | +8,3% |
| Assumed Premiums Earned | – | – | – | $5,1 M | $4,75 M | +7,3% |
| Benefits, Losses and Expenses | $49,6 M | $49,3 M | +0,7% | $192 M | $169 M | +13,8% |
| Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets | $21 jt2025-12-31 | – | – | $21 jt | – | – |
| Business Combination, Liabilities Arising from Contingencies, Amount Recognized | $1,33 M2026-03-31 | $1,33 M | 0,0% | – | – | – |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents | $498 jt2025-12-31 | $484 jt | +2,9% | $498 jt | $484 jt | +2,9% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities | – | – | – | $475 jt2024-12-31 | $183 jt | +159,6% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | $193 jt2025-12-31 | -$236 jt | +181,8% | $193 jt | -$236 jt | +181,8% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other | $2 jt2025-12-31 | $242 jt | -99,2% | $2 jt | $242 jt | -99,2% |
| Capitalized Computer Software, Amortization | – | – | – | $803 jt | $734 jt | +9,4% |
| Capitalized Computer Software, Gross | $6,69 M2025-12-31 | $6,36 M | +5,2% | $6,69 M | $6,36 M | +5,2% |
| Cash and Cash Equivalents, at Carrying Value | $10,3 M | $8,71 M | +18,8% | $9,49 M | $8,29 M | +14,5% |
| Cash and Cash Equivalents, Fair Value Disclosure | $5,69 M | $3,22 M | +76,7% | $5,18 M | $3,2 M | +62,1% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $10,3 M | $8,71 M | +18,8% | $9,49 M | $8,29 M | +14,5% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations | $02025-12-31 | $66 jt | -100,0% | $0 | $66 jt | -100,0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $116 jt | $153 jt | -24,2% | $1,2 M | $1,83 M | -34,2% |
| Ceded Premiums Earned | – | – | – | $114 jt | $66 jt | +72,7% |
| Common Stock, Dividends, Per Share, Cash Paid | $1,72 | $1,71 | +0,6% | – | – | – |
| Common Stock, Dividends, Per Share, Declared | $1,72 | $1,71 | +0,6% | $5,922023-12-31 | $5,12 | +15,6% |
| Common Stock, Par or Stated Value Per Share | $0,01 | $0,01 | 0,0% | $0,01 | $0,01 | 0,0% |
| Common Stock, Shares Authorized | 900 jt | 900 jt | 0,0% | 900 jt | 900 jt | 0,0% |
| Common Stock, Shares, Issued | 216 jt | 222 jt | -2,7% | 221 jt | 227 jt | -3,0% |
| Common Stock, Shares, Outstanding | 216 jt | 222 jt | -2,7% | 221 jt | 227 jt | -3,0% |
| Common Stock, Value, Issued | $2 jt | $2 jt | 0,0% | $2 jt | $2 jt | 0,0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $400 jt | $1,41 M | -71,6% | $6,36 M | $6,15 M | +3,4% |
| Cost of Goods and Services Sold | $5,64 M | $5,38 M | +4,8% | $21,2 M | $19,8 M | +7,2% |
| Current Federal Tax Expense (Benefit) | – | – | – | $1 M | $1,75 M | -43,0% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $199 jt | $93 jt | +114,0% |
| Current Income Tax Expense (Benefit) | – | – | – | $1,33 M | $2,29 M | -42,2% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $128 jt | $448 jt | -71,4% |
| Current Year Claims and Claims Adjustment Expense | $36,9 M | $37,3 M | -1,3% | $146 M | $125 M | +16,1% |
| Debt Securities, Available-for-sale | $26,6 M | $27,4 M | -3,1% | $27 M | $26,2 M | +2,9% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $95 jt | $639 jt | -85,1% | $631 jt | $284 jt | +122,2% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $1,56 M | $542 jt | +186,9% | $494 jt | $970 jt | -49,1% |
| Debt Securities, Available-for-sale, Allowance for Credit Loss | $60 jt | $13 jt | +361,5% | $21 jt | $6 jt | +250,0% |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Current | $60 jt | $13 jt | +361,5% | $21 jt | $6 jt | +250,0% |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Noncurrent | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Amortized Cost | $28,1 M | $27,3 M | +2,8% | $26,9 M | $26,9 M | -0,1% |
| Debt Securities, Available-for-sale, Amortized Cost, Current | $26,8 M | $26,2 M | +2,3% | $25,8 M | $25,9 M | -0,4% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 | $6,45 M | $6,42 M | +0,4% | $6,59 M | $6,28 M | +5,0% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $9,38 M | $10,4 M | -9,7% | $10,5 M | $10,6 M | -0,5% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $3,25 M | $4,87 M | -33,2% | $4,27 M | $4,83 M | -11,5% |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One | $295 jt | $280 jt | +5,4% | $241 jt | $198 jt | +21,7% |
| Debt Securities, Available-for-sale, Amortized Cost, Noncurrent | $1,27 M | $1,11 M | +14,6% | $1,12 M | $1,05 M | +6,4% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer | $2,77 M | $4,76 M | -41,7% | $4,21 M | $6,65 M | -36,7% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data per 2026-11-01